News
![The Patent Cliff Is Why AbbVie Is Moving Higher: https://www.marketbeat.com/logos/articles/med_20230727111439_chart-abbv-7272023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHBmYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--935cca24a6778feef68acd0ba705fc302dbc20e6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230727111439_chart-abbv-7272023.png?locale=us)
The Patent Cliff Is Why AbbVie Is Moving Higher
AbbVie (NYSE: ABBV) shares have been under pressure for the last 2 years as fears of the patent cliff gripped the market. The fear of rapidly declining Humira sales was not offset by hope driven by
![7 Best Cancer Stocks to Invest in Now: https://www.marketbeat.com/logos/articles/med_20230727124720_screen-shot-2023-07-27-at-124639-pm.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3hlYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--58b3da07e718bdee0eb4b30bfa9d8433ea4cb2d0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230727124720_screen-shot-2023-07-27-at-124639-pm.png?locale=us)
7 Best Cancer Stocks to Invest in Now
One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which
![Eilt: Bahnbrechende Investitionen in Kürze - Krebs vollständig geheilt. Massives Kaufsignal. Neuer 198% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB) Jetzt 198%: https://www.irw-press.at/prcom/images/messages/2023/71465/AC-280723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN1JlYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bc1e7c899e0066a6c547502bd6bd98db789982b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-280723.001.png?locale=us)
Eilt: Bahnbrechende Investitionen in Kürze - Krebs vollständig geheilt. Massives Kaufsignal. Neuer 198% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB) Jetzt 198%
Eilt: Bahnbrechende Investitionen in Kürze - Krebs vollständig geheilt. 198% Biotech Hot Stock nach 134.452% mit Biogen
28.07.23 08:02
London (www.aktiencheck.de , Anzeige)
![Eilt: Krebs vollständig geheilt - Massives Kaufsignal. Neuer 202% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71441/Ac-07-26-23-ac1.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTFhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--84042ab6ca0d73b2fb1693c1617a71eaf704c0c7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Ac-07-26-23-ac1.001.png?locale=us)
Eilt: Krebs vollständig geheilt - Massives Kaufsignal. Neuer 202% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Krebs vollständig geheilt - Massives Kaufsignal. 202% Biotech Hot Stock nach 134.452% mit Biogen ($BIIB)
26.07.23 08:02
London (www.aktiencheck.de, Anzeige)
![Masimo, Medical Device Maker Drops on Q2 Guidance, Opportunity?: https://www.marketbeat.com/logos/articles/med_20230725080758_masimo-medical-device-maker-drops-on-q2-guidance-o.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekZhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--614a8fc18118a12a2298d413534b80dc79f16456/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230725080758_masimo-medical-device-maker-drops-on-q2-guidance-o.jpg?locale=us)
Masimo, Medical Device Maker Drops on Q2 Guidance, Opportunity?
Shares of health monitoring technology maker Masimo Corporation (NASDAQ: MASI) dropped 24% to $114.30 last week due to a second-quarter performance warning. They are at their lowest level since
![Is AT&T Stock a Golden Opportunity or 'Lead' Weight?: https://www.marketbeat.com/logos/articles/med_20230724142121_is-att-stock-a-golden-opportunity-or-lead-weight.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3RaYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--47139371b1bef6b876f283c65f6ff363e036e1bf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230724142121_is-att-stock-a-golden-opportunity-or-lead-weight.png?locale=us)
Is AT&T Stock a Golden Opportunity or 'Lead' Weight?
AT&T Inc. (NYSE:T) is being haunted by a ghost of telecommunications past.
Emerging concerns about the lead content of the industry’s legacy cables spooked environmentalists and investors alike
![Sensation: Vollständige Krebsheilung - Massives Kaufsignal. Neuer 202% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71431/AC_VidacPharma_250723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEpaYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6d3d8b8570e4bf382ce9d6f5da01c21ecc42aa5a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC_VidacPharma_250723.001.png?locale=us)
Sensation: Vollständige Krebsheilung - Massives Kaufsignal. Neuer 202% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Sensation: Vollständige Krebsheilung - Massives Kaufsignal. 202% Biotech Aktientip nach 15.973% mit BioNTech ($BNTX)
25.07.23 08:02
London (www.aktiencheck.de, Anzeige)
![Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush: https://www.marketbeat.com/logos/articles/med_20230724072744_lilly-shares-up-on-versanis-deal-amid-weight-loss.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXRZYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b9f83eb09fecce9f51f50355f2bfdb6f72cf87cc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230724072744_lilly-shares-up-on-versanis-deal-amid-weight-loss.jpg?locale=us)
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
Shares of Eli Lilly & Co. (NYSE: LLY) closed 2.80% higher for the week ended July 21, a week after Lilly said it would buy Versanis, a privately held clinical-stage biopharmaceutical company
![Krebs erfolgreich geheilt - Klinische Studie mit sensationellen Ergebnissen. Massives Kaufsignal. Neuer 202% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB).: https://www.irw-press.at/prcom/images/messages/2023/71417/AC-240723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzFYYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ce9eeb8b341e0118f86fa2a40980688c7b33f060/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-240723.001.png?locale=us)
Krebs erfolgreich geheilt - Klinische Studie mit sensationellen Ergebnissen. Massives Kaufsignal. Neuer 202% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB).
Krebs erfolgreich geheilt - Klinische Studie mit sensation. Ergebnissen. 202% Biotech Hot Stock nach 134.452% mit Biogen
24.07.23 08:02
London (www.aktiencheck.de , Anzeige)
![Biotech Hot Stock meldet großartige Studienergebnisse - Massives Kaufsignal. Neuer 202% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). : https://www.irw-press.at/prcom/images/messages/2023/71408/ac-210723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1pXYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--59ffaa484dae80d9e00b22668c79ac1c349ef8a8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ac-210723.001.png?locale=us)
Biotech Hot Stock meldet großartige Studienergebnisse - Massives Kaufsignal. Neuer 202% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB).
Biotech Hot Stock meldet großartige Studienergebnisse - Kaufsignal. 202% Biotech Aktientip nach 10996% mit Pfizer ($PFE)
21.07.23 08:02
London (www.aktiencheck.de , Anzeige)
![3 Undervalued Large-Cap Stocks That Won't Be for Long: https://www.marketbeat.com/logos/articles/med_20230720112113_3-undervalued-large-cap-stocks-that-wont-be-for-lo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0ZWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8c9c62a9a42bcde03ad6af4158c8121b3b068f0a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230720112113_3-undervalued-large-cap-stocks-that-wont-be-for-lo.jpg?locale=us)
3 Undervalued Large-Cap Stocks That Won't Be for Long
The market rally is starting to extend beyond the “Magnificent 7” tech stocks. Yet many analysts and economists still believe investors may be in for a nasty pullback before the year ends.
Market
![Abbott Laboratories Has the Prescription for Higher Share Prices: https://www.marketbeat.com/logos/articles/med_20230720093702_abbott-laboratories-has-the-prescription-for-highe.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOU5WYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--79cff72b1c7a3619ad3fca2e3c869edc42d91794/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230720093702_abbott-laboratories-has-the-prescription-for-highe.jpg?locale=us)
Abbott Laboratories Has the Prescription for Higher Share Prices
Abbott Laboratories (NYSE: ABT) is a tale of two stories. The first is its recovery from the COVID-19 boost and bubble. The second is the underlying core business, which is as strong as ever.
![Acumen Soars on Alzheimer's Study...Street Sees It Doubling: https://www.marketbeat.com/logos/articles/med_20230719085627_acumen-soars-on-alzheimers-study.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWxVYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7d06de85ee32199ce1bf0eb2f291914ab8af9c0c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230719085627_acumen-soars-on-alzheimers-study.jpg?locale=us)
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
Two years removed from an IPO, Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) looks like it made a good decision to go public. Shares of the Charlottesville, Virginia-based biotechnology company
![Viasat Drops 29%: Falling Knife or Moonshot Bargain?: https://www.marketbeat.com/logos/articles/med_20230717134826_viasat-drops-29-falling-knife-or-moonshot-bargain.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3RSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6f3f3a741af7f2bd0f805bd86b3eac278d188665/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230717134826_viasat-drops-29-falling-knife-or-moonshot-bargain.jpg?locale=us)
Viasat Drops 29%: Falling Knife or Moonshot Bargain?
Last month, digital satellite telecommunications pioneer Viasat, Inc. (NASDAQ: VSAT) was on top of the world. The company had just wrapped up a $7.3 billion acquisition of U.K. rival Inmarsat to
![Eilt: Biotech Hot Stock meldet bahnbrechenden Deal - Massives Kaufsignal. Sensationelle Studienergebnisse. 20% der Patienten vollständig geheilt. Neuer 204% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Am: https://www.irw-press.at/prcom/images/messages/2023/71359/AC_VidacPharma_180723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEZSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--902ae3cd3f94e9f97c2b83a87bcad23a6074803f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC_VidacPharma_180723.001.png?locale=us)
Eilt: Biotech Hot Stock meldet bahnbrechenden Deal - Massives Kaufsignal. Sensationelle Studienergebnisse. 20% der Patienten vollständig geheilt. Neuer 204% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Am
Eilt: Biotech Hot Stock meldet bahnbrechenden Deal - Massives Kaufsignal. 204% Biotech Aktientip nach 10.996% mit Pfizer
18.07.23 08:02
London (www.aktiencheck.de, Anzeige)
![Nvidia Invested $50 million into This AI Drug Discovery Biotech: https://www.marketbeat.com/logos/articles/med_20230716132259_chart-rxrx.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlJRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c32150e596e9c48359624dcfda1c7e34ea8e1d32/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230716132259_chart-rxrx.jpg?locale=us)
Nvidia Invested $50 million into This AI Drug Discovery Biotech
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) leader
![3 Dividend Stocks That Still Make Sense in 2023: https://www.marketbeat.com/logos/articles/med_20230717061732_3-dividend-stocks-that-still-make-sense-in-2023.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0pRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b09c21eed27bad96eec4640bb14a3230dc101d64/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230717061732_3-dividend-stocks-that-still-make-sense-in-2023.jpg?locale=us)
3 Dividend Stocks That Still Make Sense in 2023
It was hard to find big stock market winners in 2022. But dividend stocks were among the better performers. Dividend-paying stocks give investors a reward for simply holding on to the stock. That
![United Health Stock Is Flying, It May Only Be The Beginning: https://www.marketbeat.com/logos/articles/med_20230714140747_united-health-stock-is-flying-it-may-only-be-the-b.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1JRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4d36d13b71836b7b38858c8bb9fdcd3f45ee1e20/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230714140747_united-health-stock-is-flying-it-may-only-be-the-b.jpg?locale=us)
United Health Stock Is Flying, It May Only Be The Beginning
The United States Economy is beginning to undergo a significant pivot, where specific industries will be rewarded with investment inflows over others. As the FED attempts to combat rampant inflation
![Eilt: 20% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 204% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). : https://www.irw-press.at/prcom/images/messages/2023/71350/AC-170723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXBRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--206c5d6d311d0708c667fd826dd1799cc6a956b8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-170723.001.png?locale=us)
Eilt: 20% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. Neuer 204% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB).
20% der Hautkrebs-Patienten vollständig geheilt - Massives Kaufsignal. 204% Biotech Hot Stock nach 134.452% mit Biogen
17.07.23 08:03
London (www.aktiencheck.de , Anzeige)
![Zillow’s Stock Is Hot...The Housing Market Is Not: https://www.marketbeat.com/logos/articles/med_20230714055235_zillows-stock-is-hot.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVpPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fa378ee14ec9d63e906a9d42e14e8c90bbbe409b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230714055235_zillows-stock-is-hot.jpg?locale=us)
Zillow’s Stock Is Hot...The Housing Market Is Not
Up more than 70% this year, Zillow Group, Inc. (NASDAQ:ZG) is one of the hottest technology stocks — and yet it's not exactly making a big splash.
In a market focused on artificial intelligence
![Eilt: Hautkrebs-Studie mit sensationellen Ergebnissen - Massives Kaufsignal. Neuer 204% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71337/AC-140723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1ZPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--63a6a13be77b3f06723db5855005e6b1684040e3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-140723.001.png?locale=us)
Eilt: Hautkrebs-Studie mit sensationellen Ergebnissen - Massives Kaufsignal. Neuer 204% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Hautkrebs-Studie mit sensationellen Ergebnissen - Massives Kaufsignal. 204% Biotech Aktientip nach 15.973% mit BioNTech
14.07.23 08:02
London (www.aktiencheck.de , Anzeige)
![3 Biotech Stocks to Buy for Long-Term Gains: https://www.marketbeat.com/logos/articles/med_20230712120806_3-biotech-stocks-to-buy-for-long-term-gains.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemROYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c04e98cd4261cd61ec3e977f2402dff8e942c65/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230712120806_3-biotech-stocks-to-buy-for-long-term-gains.jpg?locale=us)
3 Biotech Stocks to Buy for Long-Term Gains
Suppose you’re looking for a sector that will benefit from an end to the Federal Reserve’s interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with
![Sensationeller Erfolg im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 206% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 206% mit Biotech Hot Stock: https://www.irw-press.at/prcom/images/messages/2023/71323/AC-130723-2.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVpNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--de98086908f29e9baed0751938cefe6b077f7f63/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-130723-2.001.png?locale=us)
Sensationeller Erfolg im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 206% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 206% mit Biotech Hot Stock
Sensationeller Erfolg im Kampf gegen Hautkrebs - Massives Kaufsignal. 206% Biotech Aktientip nach 134.452% mit Biogen
13.07.23 08:18
London (www.aktiencheck.de, Anzeige)
![Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71305/Aktiencheck_Vidac_120723.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenRMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5b3f64bfef07fa8bd92ce1bf962296d13aace5ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck_Vidac_120723.001.png?locale=us)
Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Erstkl. Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. 208% Biotech Hot Stock nach 31.205% mit Amgen
12.07.23 08:02
London (www.aktiencheck.de, Anzeige)
![Accolade: A Rising Personalized AI-Powered Healthcare Platform: https://www.marketbeat.com/logos/articles/med_20230709131618_chart-accd.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0pKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--81a0aaf652672922732493576c882991a89eb45f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230709131618_chart-accd.jpg?locale=us)
Accolade: A Rising Personalized AI-Powered Healthcare Platform
Accolade Inc. (NASDAQ: ACCD) is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people